Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.32 |
| ▸ | MME | P08473 | 7/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ACE | P12821 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ECE1 | P42892 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259179 | 1.00 | SLC15A2 (0.38) | SLC15A2PTGS1GSTK1GLO1MME | |
| SCHEMBL31323969 | 0.94 | SLC15A2 (0.34) | SLC15A2PTGS1GSTK1GLO1 | |
| SCHEMBL29630686 | 0.91 | OPRD1 (0.38) | SLC15A2 | |
| SCHEMBL30441904 | 0.91 | SLC15A2 (0.37) | SLC15A2PTGS1GSTK1 | |
| SCHEMBL29793344 | 0.91 | PTGS1 (0.37) | SLC15A2PTGS1GSTK1GLO1 | |
| SCHEMBL20397507 | 0.91 | SLC15A2 (0.41) | SLC15A2 | |
| SCHEMBL20397438 | 0.91 | SLC15A2 (0.41) | SLC15A2 | |
| SCHEMBL29793386 | 0.91 | PTGS1 (0.39) | PTGS1GSTK1GLO1 | |
| SCHEMBL29031269 | 0.91 | PTGS1 (0.39) | PTGS1GSTK1GLO1 | |
| SCHEMBL29793028 | 0.90 | PTGS1 (0.36) | PTGS1GSTK1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865857-B2 | Medical device with predefined activated cellular integration | SOFRADIM PRODUCTION (FR) | 2014-10-21 | — | — | US | claimed |
| US-4732155-A | Implantable chemoattractant system | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1988-03-22 | — | — | US | claimed |
| US-20170267628-A1 | ISOMER-SELECTIVE SYNTHESIS OF METHANOFULLERENES | NANO-C, INC. | 2017-09-21 | — | — | US | disclosed |
| US-9586989-B1 | Non-toxic skin cancer therapy with copper peptides | SKIN BIOLOGY, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-8865857-B2 | Medical device with predefined activated cellular integration | SOFRADIM PRODUCTION (FR) | 2014-10-21 | — | — | US | disclosed |
| CN-102387792-B | Solid preparation | LINTEC CORP | 2013-08-14 | — | — | CN | disclosed |
| US-20130143976-A1 | MEDICAL DEVICE WITH PREDEFINED ACTIVATED CELLULAR INTEGRATION | SOFRADIM PRODUCTION (FR) | 2013-06-06 | — | — | US | disclosed |
| EP-2588153-A2 | MEDICAL DEVICE WITH PREDEFINED ACTIVATED CELLULAR INTEGRATION | Sofradim Production (FR) | 2013-05-08 | — | — | EP | disclosed |
| CN-102387792-A | Solid preparation | LINTEC CORP | 2012-03-21 | — | — | CN | disclosed |
| US-20120034276-A1 | SOLID PREPARATION | ASKA PHARMACEUTICAL CO., LTD. | 2012-02-09 | — | — | US | disclosed |
| EP-2412366-A1 | SOLID PREPARATION | LINTEC Corporation (JP) | 2012-02-01 | — | — | EP | disclosed |
| EP-0884389-A1 | Enzyme participating in C-terminal amidation, and method of preparing same and use thereof | SHISEIDO COMPANY LIMITED (JP) | 1998-12-16 | — | — | EP | disclosed |
| EP-0882768-A2 | Method for producing of phthalocyanine compound | NIPPON SHOKUBAI CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0438600-B1 | ENZYMES WHICH PARTICIPATE IN C-TERMINAL AMIDATION, AND PRODUCTION AND USE THEREOF | SHISEIDO CO LTD (JP) | 1996-02-07 | — | — | EP | disclosed |
| EP-0666318-A1 | Enzyme participating in c-terminal amidation, and method of preparing same and use thereof | SHISEIDO COMPANY LIMITED (JP) | 1995-08-09 | — | — | EP | disclosed |
| US-5354675-A | Amidation of glycine | SHISEIDO COMPANY LTD. (JP) | 1994-10-11 | — | — | US | disclosed |
| EP-0447547-B1 | C-TERMINUS AMIDATION ENZYME COMPOSITION, PROCESS FOR ITS PREPARATION AND ITS USE | SHISEIDO CO LTD (JP) | 1994-07-27 | — | — | EP | disclosed |
| EP-0447547-A1 | C-TERMINUS AMIDATION ENZYME COMPOSITION, PROCESS FOR ITS PREPARATION AND ITS USE | SHISEIDO COMPANY LIMITED (JP) | 1991-09-25 | — | — | EP | disclosed |
| EP-0438600-A1 | ENZYMES WHICH PARTICIPATE IN C-TERMINAL AMIDATION, AND PRODUCTION AND USE THEREOF | SHISEIDO COMPANY LIMITED (JP) | 1991-07-31 | — | — | EP | disclosed |
| US-4732155-A | Implantable chemoattractant system | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1988-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143976-A1 | MEDICAL DEVICE WITH PREDEFINED ACTIVATED CELLULAR INTEGRATION | CCL2, MIF, C3AR1 | SLC15A2 3528/4885PTGS1 731/4885GSTK1 678/4885 |
| US-20170267628-A1 | ISOMER-SELECTIVE SYNTHESIS OF METHANOFULLERENES | GABRB1, GABRB3, GABRB2 | SLC15A2 3912/4885PTGS1 3865/4885GSTK1 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.